L. Kandalaft

Discipline

Economies et finances (1)

Type de document

Articles (8) Recensions (3)

Co-auteur

Date

Source

Mot-clé

cancer (5) Treatment (5) Cancer (5) Immunotherapy (5) Cancer (5) Immunotherapy (5) T cells (4) Patients (4) Human beings (4) Lymphocytes (4) Patients (4) temps (durée) (3) système immunitaire (3) maladie (3) Control (3) Immune system (3) Time (3) Impact (3) Cells (3) Utilization (3) maladie (3) puits (2) toxicité (2) thérapie (2) méthode (2) procès (2) survie (2) Context (2) Chemotherapy (2) Cases (2)

Documents écrit par L. Kandalaft (8) | parle de L. Kandalaft (0)

Long-term benefit of lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma (MPM): final efficacy and translational data of the SAKK 17/16 study.
M. Mark et al.
Guillain-Barré syndrome after adoptive cell therapy with tumor-infiltrating lymphocytes.
A. Orcurto et al.
Adenosine mediates functional and metabolic suppression of peripheral and tumor-infiltrating CD8+ T cells.
B. Mastelic-Gavillet et al. (10 oct. 2019)
50-Gy Stereotactic Body Radiation Therapy to the Dominant Intraprostatic Nodule: Results From a Phase 1a/b Trial.
F.G. Herrera et al. (1 févr. 2019)
Cryoablation and Immunotherapy: An Enthralling Synergy to Confront the Tumors.
C. Yakkala et al. (2019)
Emerging Opportunities of Radiotherapy Combined With Immunotherapy in the Era of Breast Cancer Heterogeneity.
P.G. Tsoutsou et al. (2018)
A cancer vaccine with dendritic cells differentiated with GM-CSF and IFNα and pulsed with a squaric acid treated cell lysate improves T cell priming and tumor growth control in a mouse model.
A. Mookerjee et al. (2018)
The era of bioengineering: how will this affect the next generation of cancer immunotherapy?
M. Graciotti et al. (19 juin 2017)